Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Elife|September 21, 2018
UBE2G1 governs the destruction of cereblon neomorphic substratesGang Lu, Stephanie Weng, Mary Matyskiela, et al.Cancer Research|February 18, 2010
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancerErik Kupperman, Edmund C Lee, Yueying Cao, et al.Cancer Research|August 3, 2005
Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulatorsWilliam L Perry, Robert L Shepard, Janardhan Sampath, et al.Molecular Cancer Therapeutics|December 19, 2006
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomibMark J Williamson, Jonathan L Blank, Frank J Bruzzese, et al.Journal of Medicinal Chemistry|November 14, 2015
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)Han-Jie Zhou, Jinhai Wang, Bing Yao, et al.ACS Chemical Biology|January 15, 2019
CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer ActivityVictoria A Assimon, Yangzhong Tang, Jesse D Vargas, et al.Blood|June 8, 2010
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphomaMichael A Milhollen, Tary Traore, Jennifer Adams-Duffy, et al.Nature Chemical Biology|September 8, 2018
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrateMary E Matyskiela, Suzana Couto, Xinde Zheng, et al.Blood Cancer Discovery|May 24, 2021
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignanciesAline Renneville, Jessica A Gasser, Daniel E Grinshpun, et al.Cancer Cell|November 12, 2015
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein HomeostasisDaniel J Anderson, Ronan Le Moigne, Stevan Djakovic, et al.Pageof 5